Reviewing Global Cord Blood Corporation (CO)’s and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s results

We are contrasting Global Cord Blood Corporation (NYSE:CO) and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood Corporation N/A 0.00 N/A 0.27 24.01
Intercept Pharmaceuticals Inc. 196.09M 13.25 317.92M -10.75 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Global Cord Blood Corporation and Intercept Pharmaceuticals Inc.

Profitability

Table 2 provides the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Global Cord Blood Corporation 0.00% 7.2% 3.8%
Intercept Pharmaceuticals Inc. -162.13% -615.8% -60.3%

Risk & Volatility

Global Cord Blood Corporation’s volatility measures that it’s 62.00% less volatile than Standard & Poor’s 500 due to its 0.38 beta. Competitively, Intercept Pharmaceuticals Inc. is 51.00% more volatile than Standard & Poor’s 500, because of the 1.51 beta.

Liquidity

The current Quick Ratio of Global Cord Blood Corporation is 9.6 while its Current Ratio is 9.7. Meanwhile, Intercept Pharmaceuticals Inc. has a Current Ratio of 3.7 while its Quick Ratio is 3.7. Global Cord Blood Corporation is better positioned to pay off its short-term and long-term debts than Intercept Pharmaceuticals Inc.

Dividends

Global Cord Blood Corporation dividend pay is $0.08 per share with 1.18% dividend yield annually. No dividend is paid out for Intercept Pharmaceuticals Inc.

Analyst Ratings

Global Cord Blood Corporation and Intercept Pharmaceuticals Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Global Cord Blood Corporation 0 0 0 0.00
Intercept Pharmaceuticals Inc. 1 3 11 2.73

Intercept Pharmaceuticals Inc. on the other hand boasts of a $163.69 consensus price target and a 105.85% potential upside.

Institutional & Insider Ownership

Institutional investors held 18.2% of Global Cord Blood Corporation shares and 70.8% of Intercept Pharmaceuticals Inc. shares. About 49.6% of Global Cord Blood Corporation’s share are held by insiders. Competitively, 22.9% are Intercept Pharmaceuticals Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Global Cord Blood Corporation -1.35% -7.19% -2.08% -2.37% -31.39% 2.02%
Intercept Pharmaceuticals Inc. 0.79% -4.33% -20.02% -18.89% 23.1% -12.43%

For the past year Global Cord Blood Corporation had bullish trend while Intercept Pharmaceuticals Inc. had bearish trend.

Summary

Global Cord Blood Corporation beats on 9 of the 12 factors Intercept Pharmaceuticals Inc.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.